Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08), Zacks reports.
Checkpoint Therapeutics Price Performance
NASDAQ CKPT opened at $3.62 on Thursday. Checkpoint Therapeutics has a fifty-two week low of $1.36 and a fifty-two week high of $3.97. The stock’s 50-day moving average is $2.76 and its two-hundred day moving average is $2.32. The firm has a market cap of $162.97 million, a P/E ratio of -1.97 and a beta of 1.23.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, September 16th.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
See Also
- Five stocks we like better than Checkpoint Therapeutics
- Do ETFs Pay Dividends? What You Need to Know
- Top 3 R&D-Driven Stocks Showing Strong Profit and Momentum
- Investing in Travel Stocks Benefits
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Tariff Troubles: 3 Stocks Planning Higher Prices
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
